Liquidia has undergone a dramatic transformation, with revenue surging from $3.1M in 2025Q1 to $171.7M in 2026Q2, driven by generic treprostinil distribution, and gross margins expanding to 93.3%. The company achieved profitability with net income of $74.7M in...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 18.4% YoY in 2026Q2, with gross margin expanding to 93.3% and operating margin reaching 49.8%, driven by the generic treprostinil scale-up.
Liquidia will present four posters at the PHA 2026 International PH Conference, showcasing advancements in respiratory and vascular disease treatments.
A bullish case for Liquidia was discussed on wallstreetbets, highlighting potential upside in the stock.
MarketBeat provides access to Liquidia's complete SEC filings through 2026, indicating transparency and regulatory compliance.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | $0.74-2.4% vs $0.76 | $172M+1.9% vs $168M |
Q2 2026 May 11, 2026 | $0.52+52.9% vs $0.34 | $133M+11.2% vs $119M |
Q2 2026 Mar 5, 2026 | $0.15+87.5% vs $0.08 | $92M+3.9% vs $89M |
Q4 2025 Nov 3, 2025 | -$0.04+91.1% vs -$0.45 | $54M-32.7% vs $81M |
California State Teachers Retirement System raised its holdings in shares of Liquidia Corporation (NASDAQ: LQDA) by 8,055.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,907,594 shares of the company's stock after buying an additional 5,835,156 shares during the
Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc patients No therapy is currently approved in the U.S. to treat SSc-RP and management options are limited and often inadequate for patients with more severe disease Liquidia plans to initiate RE-WARM, a Phase 2a dose-finding study of YUTREPIA in SSc-RP, in the fourth quarter of 2026 MORRISVILLE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to YUTREPIA® (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP).
Benchmark LQDA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Liquidia Corporation (LQDA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $67.49 | $6B | -84.36 | 1031.18% | -43.53% | -112.97% | — | |
| $489.42 | $20.77B | 17.57 | 10.61% | 41.56% | 20.18% | — | |
| $3.34 | $1.07B | 167.00 | 22.23% | -11.08% | — | — | |
| $20.24 | $1.49B | 6.13 | 18.52% | 80.56% | 30.03% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $118.34 | $25.65B | -18.46 | 66.73% | -76.94% | -111.26% | — |
Liquidia Corporation (LQDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Liquidia Corporation (LQDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Jun 17, 2026·SEC
Jun 8, 2026·SEC
Get notified when LQDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Liquidia Corporation (LQDA) stock FAQ — growth, dividends, profitability & financials explained
Liquidia Corporation (LQDA) reported $450.9M in revenue for fiscal year 2025. This represents a 3312% increase from $13.2M in 2016.
Liquidia Corporation (LQDA) grew revenue by 1031.2% over the past year. This is strong growth.
Yes, Liquidia Corporation (LQDA) is profitable, generating $138.6M in net income for fiscal year 2025 (-43.5% net margin).
Liquidia Corporation (LQDA) has a return on equity (ROE) of -113.0%. Negative ROE indicates the company is unprofitable.
Liquidia Corporation (LQDA) generated $60.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
